385 related articles for article (PubMed ID: 12939122)
1. Citrus aurantium as a thermogenic, weight-reduction replacement for ephedra: an overview.
Preuss HG; DiFerdinando D; Bagchi M; Bagchi D
J Med; 2002; 33(1-4):247-64. PubMed ID: 12939122
[TBL] [Abstract][Full Text] [Related]
2. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects.
Belza A; Frandsen E; Kondrup J
Int J Obes (Lond); 2007 Jan; 31(1):121-30. PubMed ID: 16652130
[TBL] [Abstract][Full Text] [Related]
3. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update.
Haaz S; Fontaine KR; Cutter G; Limdi N; Perumean-Chaney S; Allison DB
Obes Rev; 2006 Feb; 7(1):79-88. PubMed ID: 16436104
[TBL] [Abstract][Full Text] [Related]
4. Increase in the thermic effect of food in women by adrenergic amines extracted from citrus aurantium.
Gougeon R; Harrigan K; Tremblay JF; Hedrei P; Lamarche M; Morais JA
Obes Res; 2005 Jul; 13(7):1187-94. PubMed ID: 16076988
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial.
Gadde KM; Yonish GM; Wagner HR; Foust MS; Allison DB
Int J Obes (Lond); 2006 Jul; 30(7):1138-42. PubMed ID: 16418753
[TBL] [Abstract][Full Text] [Related]
6. Consumption of dietary supplements containing Citrus aurantium (bitter orange)--2004 California Behavioral Risk Factor Surveillance Survey (BRFSS).
Klontz KC; Timbo BB; Street D
Ann Pharmacother; 2006 Oct; 40(10):1747-51. PubMed ID: 16968826
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic agents for weight reduction.
Haller C; Schwartz JB
J Gend Specif Med; 2002; 5(5):16-21. PubMed ID: 12380196
[TBL] [Abstract][Full Text] [Related]
8. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial.
Zelissen PM; Stenlof K; Lean ME; Fogteloo J; Keulen ET; Wilding J; Finer N; Rössner S; Lawrence E; Fletcher C; McCamish M;
Diabetes Obes Metab; 2005 Nov; 7(6):755-61. PubMed ID: 16219020
[TBL] [Abstract][Full Text] [Related]
9. Screening for in vivo (anti)estrogenic activity of ephedrine and p-synephrine and their natural sources Ephedra sinica Stapf. (Ephedraceae) and Citrus aurantium L. (Rutaceae) in rats.
Arbo MD; Franco MT; Larentis ER; Garcia SC; Sebben VC; Leal MB; Dallegrave E; Limberger RP
Arch Toxicol; 2009 Jan; 83(1):95-9. PubMed ID: 18651134
[TBL] [Abstract][Full Text] [Related]
10. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
Dastjerdi MS; Kazemi F; Najafian A; Mohammady M; Aminorroaya A; Amini M
Int J Obes (Lond); 2007 Apr; 31(4):713-7. PubMed ID: 16969361
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a novel calcium/potassium salt of (-)-hydroxycitric acid in weight control.
Preuss HG; Garis RI; Bramble JD; Bagchi D; Bagchi M; Rao CV; Satyanarayana S
Int J Clin Pharmacol Res; 2005; 25(3):133-44. PubMed ID: 16366421
[TBL] [Abstract][Full Text] [Related]
12. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
Kopelman P; Bryson A; Hickling R; Rissanen A; Rossner S; Toubro S; Valensi P
Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261
[TBL] [Abstract][Full Text] [Related]
13. [Ephedrine and ephedra in weight loss products and other preparations].
van der Hooft CS; Stricker BH
Ned Tijdschr Geneeskd; 2002 Jul; 146(28):1335-6. PubMed ID: 12148223
[TBL] [Abstract][Full Text] [Related]
14. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
15. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
16. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
Anderson JW; Schwartz SM; Hauptman J; Boldrin M; Rossi M; Bansal V; Hale CA
Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
[TBL] [Abstract][Full Text] [Related]
17. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
Harrison SA; Fecht W; Brunt EM; Neuschwander-Tetri BA
Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
[TBL] [Abstract][Full Text] [Related]
18. Availability of weight-loss supplements: Results of an audit of retail outlets in a southeastern city.
Sharpe PA; Granner ML; Conway JM; Ainsworth BE; Dobre M
J Am Diet Assoc; 2006 Dec; 106(12):2045-51. PubMed ID: 17126636
[TBL] [Abstract][Full Text] [Related]
19. The beta-adrenergic antagonist propranolol partly abolishes thermogenic response to bioactive food ingredients.
Belza A; Gille MB; Schultz John S; Kondrup J
Metabolism; 2009 Aug; 58(8):1137-44. PubMed ID: 19497591
[TBL] [Abstract][Full Text] [Related]
20. Short-term and long-term in vivo exposure to an ephedra- and caffeine-containing metabolic nutrition system does not induce cardiotoxicity in B6C3F1 mice.
Ray S; Phadke S; Patel C; Hackman RM; Stohs S
Arch Toxicol; 2005 Jun; 79(6):330-40. PubMed ID: 15895207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
